In a Hatch-Waxman litigation involving a drug for asthma, CRA’s life sciences experts were asked to assess commercial success and its nexus to the patent. In this case, the patent involved a new once-daily dosing schedule. To assess nexus, CRA’s team examined sales in countries that approved the patented dosing regimen to sales in countries that did not and examined any changes in sales in countries that adopted the dosing regimen after launch. CRA found that the patented feature could not explain sales. CRA’s consultants submitted expert reports and deposition testimony. Following an at-risk launch, the case ultimately settled.
CRA consultants named top experts in the 2025 IAM Patent 1000 rankings
Fourteen CRA consultants were recognized as leading economic, financial, and licensing expert witnesses by Intellectual Asset Management (IAM). The IAM Patent...